• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH Studying Approved and Investigational Therapies for Use Against COVID-19

NIH Studying Approved and Investigational Therapies for Use Against COVID-19

October 19, 2020

The National Institute of Allergy and Infectious Diseases (NIAID) has begun a phase 2 study of the potential of approved therapies and late-stage investigational drugs for hospitalized COVID-19 patients.

The study, termed the ACTIV-5 Big Effect Trial (ACTIV-5/BET), is enrolling adults with COVID-19 at up to 40 sites in the U.S. It is being conducted in partnership with the National Institutes of Health’s Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.

In the randomized ACTIV-5/BET trial, licensed drugs and investigational therapies that show promise against COVID-19 compared with controls will be propelled into larger COVID-19 trials. Around 100 hospitalized patients will be randomly assigned to each study arm. No more than three investigational therapies will be tested at once.

The first candidate to be tested in the trial includes monoclonal antibody risankizumab from Boehringer Ingelheim and AbbVie. This drug is currently FDA-approved for severe plaque psoriasis, but ACTIV-5/BET will test it in combination with remdesivir vs. placebo.

ACTIV-5/BET will also test lenzilumab, Humanigen’s late-stage investigational drug for the prevention and treatment of cytokine storm, in combination with remdesivir. 

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing